Clinical trials: Anastrozole
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
SMMART Adaptive Clinical Treatment (ACT) Trial
SMMART-ACT is a feasibility pilot study to determine if testing samples from a participant's cancer using a precision medicine approach can be used to identify specific drugs or drug combinations that can help control their…
- Conditions
- Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma
- Trial name
- NCT05238831
- Testing
- Alectinib, Alpelisib, Anastrozole
- Sponsor
- OHSU Knight Cancer Institute
Cerebral Blood Flow, Cerebral Blood Flow Regulation
The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans
Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute.
- Conditions
- Cerebral Blood Flow, Cerebral Blood Flow Regulation, Sex Differences, Exercise
- Trial name
- NCT07212712
- Testing
- GnRH antagonist, Estradiol (E2), Testosterone
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Breast Cancer
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer
This study is aim to evaluate the efficacy and safety of bicalutamide and aromatase inhibitor in ER(+)/AR(+)/HER2(-) metastatic breast cancer patients who have disease progression after treatment of an aromatase inhibitor.
- Trial name
- BETTER (NCT02910050)
- Testing
- Bicalutamide, Aromatase Inhibitor
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Xu fei
Advanced Breast Cancer
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)
To compare the efficacy and safety of ribociclib in combination with aromatase inhibitor and physician's choice of chemotherapy sequential endocrine therapy in the first-line treatment of ER medium to low expression/HER2-negative…
- Trial name
- NCT06656624
- Testing
- Ribociclib combined with AI±OFS, physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS
- Where
- China
- Volunteers
- 190 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
Breast Cancer, Neoadjuvant Endocrine Therapy
Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia
Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.
- Trial name
- NEMO (NCT05800197)
- Testing
- Tamoxifen 20mg, Anastrozole 1mg, Letrozole 2.5mg
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Gynecomastia
Gynecomastia Extension Study
The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another anastrozole study).
- Trial name
- NCT00637182
- Testing
- Anastrozole
- Sponsor
- AstraZeneca
Breast Cancer, Xerostomia
Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors
The 3 Specific Aims are (1) To determine the prevalence, incidence and severity of oral conditions in postmenopausal early stage breast cancer survivors within the first 18 months of adjuvant Aromatase Inhibitor(AI) therapy, (2)…
- Trial name
- NCT01272570
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Hypopituitarism
Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys
The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone.
- Trial name
- NCT00133354
- Testing
- Arimidex (Anastrozole), Growth Hormone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Nemours Children's Clinic
Metastatic Breast Cancer, Estrogen Receptor Positive Tumor
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women
Fulvestrant is an ER antagonist with no agonist effects, which binds, blocks and degrades the ER. Fulvestrant is comparable to third-generation aromatase inhibitors in terms of efficacy and tolerability for patients who have…
- Conditions
- Metastatic Breast Cancer, Estrogen Receptor Positive Tumor, Breast Cancer Nos Premenopausal
- Trial name
- FLAG (NCT01266213)
- Testing
- Fulvestrant plus Goserelin, Anastrozole plus Goserelin, Goserelin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Samsung Medical Center
Metabolic Syndrome
Insulin Sensitivity in Men With the Metabolic Syndrome
The metabolic syndrome is a medical condition defined by high levels of cholesterol in the blood, high blood pressure, central obesity (gain in fat around the region of the stomach), and insulin resistance (body responds less…
- Trial name
- NCT00433173
- Testing
- intravenous glucose tolerance test, testosterone, anastrozole
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Female Breast Cancer
Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
The study is a prospective multi-center randomized control clinical trial which is sponsored by the researchers. The purpose of this study is to determine the effectiveness of adjuvant endocrine therapy for operable ER-beta…
- Trial name
- AETNBC (NCT02089854)
- Testing
- Toremifene; Anastrozole
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Peking Union Medical College Hospital
HR+/HER2+ Early Breast Cancer
Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
This prospective, response-adapted phase II study evaluates the efficacy and safety of neoadjuvant fovinaciclib in combination with aromatase inhibitors and dual HER2 blockade in patients with HR-positive/HER2-positive early…
- Trial name
- TAYLOR-003 (NCT07616427)
- Testing
- Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Cancer of Breast
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with…
- Conditions
- Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
- Trial name
- NCT02476786
- Testing
- FACT-B, Goserelin, Anastrozole
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
This is a randomized study comparing the use of Anastrozole before and continuing during radiotherapy for breast cancer compared to the use of anastrozole after irradiation.
- Trial name
- NCT00126360
- Testing
- Timing of Anastrozole in respect to radiotherapy
- Where
- 4 sites in Australia
- Volunteers
- 100 people
- Sponsor
- St George Hospital, Australia
Stage IIA Breast Cancer, Stage IIB Breast Cancer
Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
This pilot clinical trial studies chemotherapy before surgery and tissue sample collection in patients with stage IIA-IIIC breast cancer.
- Conditions
- Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01897441
- Testing
- Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant and exemestane, anastrozole, or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells and by…
- Trial name
- NCT00688194
- Testing
- anastrozole, exemestane, fulvestrant
- Where
- Italy
- Volunteers
- 396 people
- Sponsor
- Gruppo Italiano Mammella (GIM)
Breast Cancer
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are…
- Trial name
- NCT00259090
- Testing
- Fulvestrant, Anastrazole
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Breast Cancer, Bone Density
Arimidex Bone Mass Index and Oral Bisphosphonates
To investigate the management of bone health in postmenopausal women with early breast cancer (BCA) scheduled to receive anastrozole.
- Trial name
- ARBI (NCT00809484)
- Where
- Greece
- Volunteers
- 220 people
- Sponsor
- Hellenic Breast Surgeons Society
Breast Neoplasm Female
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Given the uncertain benefit in efficacy of adding CDK 4/6 to first rather than second line endocrine treatment, the aim of this project is to evaluate whether the sequence of an aromatase inhibitor plus CDK 4/6 in first line…
- Trial name
- NCT03425838
- Testing
- CDK 4/6 inhibitor, Non-Steroidal Aromatase Inhibitor, Fulvestrant
- Where
- 72 sites in Netherlands
- Volunteers
- 1,050 people
- Sponsor
- Borstkanker Onderzoek Groep